The Optimal Therapeutic Window for Nonbioartificial Liver Support in Acute-On-Chronic Liver Failure: A Meta-Analysis and Meta-Regression Based on Baseline MELD Score

Original title: The Optimal Therapeutic Window for Nonbioartificial Liver Support in Acute-On-Chronic Liver Failure: A Meta-Analysis and Meta-Regression Based on Baseline MELD Score.

NBALS efficacy in ACLF remains controversial.

By Li, Liu, Shao +5Journal of clinical apheresisOct 1, 2026

Score█████░░░░░5.2

Key numbers

95% CI

VerdictWorth a reader's time today.

Read the original

Abstract

NBALS efficacy in ACLF remains controversial. We aimed to determine if a "therapeutic window" exists by stratifying clinical outcomes based on baseline Model for End-Stage Liver Disease (MELD) scores. We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs and PSM-cohorts comparing NBALS to standard medical therapy (SMT). Primary outcome was 28-day mortality; MELD-stratified subgroup analyses and random-effects meta-regression were performed. Eleven studies (comprising 12 datasets) involving 1958 patients (991 NBALS vs. 967 SMT) were included. Overall, NBALS significantly reduced 28-day mortality compared with SMT (pooled RR 0.72, 95% CI [0.63-0.83], I2 = 2.8%). Subgroup analysis suggested a clinical trend toward a distinct therapeutic window: the survival benefit was most significant in the Intermediate MELD group (25-30) (RR 0.65, 95% CI [0.52-0.81], I2 = 0%) and the High MELD group (> 30) (RR 0.75, 95% CI [0.58-0.98], I2 = 0%), while substantial uncertainty exists regarding the survival benefit in the Low MELD group (< 25) (RR 0.49, 95% CI [0.08-2.81], I2 = 67.9%). Meta-regression confirmed that the maximum survival benefit of NBALS is concentrated within a baseline MELD range of approximately 25 to 32. Furthermore, NBALS group achieved a significantly higher reduction in total bilirubin compared to SMT (pooled MD 98.15, 95% CI [66.50-129.79], I2 = 99.2%). NBALS significantly improves short-term survival in ACLF, suggesting a potential therapeutic window around a baseline MELD range of 25-32. Early stratification based on disease severity is crucial for optimizing NBALS application. Trial Registration: PROSPERO CRD420261334987.

Jiahao Li, Yang Liu, Jianying Shao, Yali Cheng, Xiangkai Zeng, Han Li, Haoqian Tan, Junying Liu

The editor's rubric

Heuristic review

Dimension	Level	Weight	What that level means
Leverage	███░░ 3	10%	A method or resource many groups across the field will adopt within a year.
Magnitude	██░░░ 2	20%	Solid incremental gain on a meaningful problem.
Evidence	█████ 5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	██░░░ 2	8%	A new combination of known ideas.
Trajectory	██░░░ 2	5%	Some room to improve with obvious engineering.
Stakes	███░░ 3	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (many tasks); design (meta-analysis); verification (confidence interval, error bars, multiple benchmarks); stakes (mortality, prevention or cure).

How the score was computed

rank-2026-09-29

Score█████░░░░░5.2

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Merit: 6.6 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.2 / 10; Shrunk toward the desk prior by editor confidence (46%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 98%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Oct 1, 2026, 06:17 UTC)
Field-weighted citation impact0 (reference 3, via openalex, Oct 1, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v2 on Oct 1, 2026, 06:17 UTC. Paper type: clinical.
Categories: Meta-Analysis, research-article, Journal Article, Humans, Treatment Outcome, Severity of Illness Index, Regression Analysis, End Stage Liver Disease, Acute-On-Chronic Liver Failure, Meld Score
BRIEF, No.3 in the Medicine edition of October 1, 2026.